Joey Bose’s Post

❗BREAKING❗1st Patient Dosed in Ph 1 Clinical Trial Last night 💉 we dosed our first patient in our Phase 1 clinical trial of CYT-108 for the treatment of osteoarthritis. The patient received 25mg of CYT-108, our recombinant Alpha-2-Macroglobulin variant. They were observed for 30 minutes and no acute adverse events were detected. This event marks our transition from a preclinical research company to a clinical-stage company, a massive milestone that underscores our commitment to transforming the treatment of osteoarthritis. 📅 Timeline and Next Steps This patient will receive their final dose in late September, with the last follow-up scheduled for January 2025. Over the next two months, we anticipate enrolling and dosing approximately 20 more patients, keeping us on track for the Phase 1 clinical report to be published in June 2025. Each step brings us closer to our goal of providing a disease-modifying treatment for osteoarthritis, potentially benefiting millions of patients worldwide. Many more updates to come! #arthritis #regenerativemedicine #clinicaltrials #Cytonics #biotechnology

❗BREAKING❗1st Patient Dosed in Ph 1 Clinical Trial Last night 💉 we dosed our first patient in Cytonics Corporation's Phase 1 clinical trial of CYT-108 for the treatment of osteoarthritis. The patient received 25mg of CYT-108, our recombinant Alpha-2-Macroglobulin variant. They were observed for 30 minutes and no acute adverse events were detected. This event marks our transition from a preclinical research company to a clinical-stage company, a massive milestone that underscores our commitment to transforming the treatment of osteoarthritis. 📅 Timeline and Next Steps This patient will receive their final dose in late September, with the last follow-up scheduled for January 2025. Over the next two months, we anticipate enrolling and dosing approximately 20 more patients, keeping us on track for the Phase 1 clinical report to be published in June 2025. Each step brings us closer to our goal of providing a disease-modifying treatment for osteoarthritis, potentially benefiting millions of patients worldwide. Many more updates to come! #arthritis #regenerativemedicine #clinicaltrials #Cytonics #biotechnology

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive lung disease with a pressing need for new therapeutics. At Aragen, we are at the forefront of developing clinically relevant models, including rodent, ex vivo, and in vitro models, to drive drug discovery for IPF.   Our bleomycin-induced pulmonary fibrosis model stands out for its reproducibility, reduced animal mortality, and consistent disease induction. This robust model has accelerated many drug candidates beyond the preclinical phase, supporting both therapeutic and prophylactic development. Click here https://lnkd.in/gRETBMWy to know more about our IPF drug development services and to partner with us to enhance your IPF drug development pipeline write to us at info@aragen.com #drugdevelopment #ipf #therapeutic #prophylactic #endtoendsolutions #pulmonaryfibrosis #brochure #preclinical #exvivo #invitro #lungdisease

🔔 I’m excited to share our latest article on the dilemmas we face in precision oncology and molecular diagnostics. Here, we use PARP inhibitors / HRD testing as an example to illustrate our challenges. There is currently no harmonisation regarding such complex biomarkers as HRD, making it difficult to assess the clinical utility of tests and ensure uniformity in treatment decision-making. 🔑 We propose measures to align biomarker definitions and establish minimum analytical performance characteristics for diagnostics to ensure equitable and sustainable access to precision medicine. 👇 Check our paper in Cancer Cell and let us know your thoughts! 💭 https://lnkd.in/ewrGRm_N Thanks to my co-author's Olga Kholmanskikh, David Thomas, Simone Koole & Hans Gelderblom,... but also Reena Philip & Ana Trullas for sharing their insights regarding the regulatory aspects of companion diagnostics within European Medicines Agency & FDA #ivd #ivdr #moleculardiagnostics #companiondiagnostics #precisionmedicine #precisiononcology #parpinhibitors #hrd #mdx #drugdevelopment #biomarker #clinicalutility #hta

Join us for an exciting deep dive into the specifics of organoid-based drug screening with our detailed webinar! 👏 👏 Dr. Marrit Putker, a leading expert in organoid technology, will guide us through the entire organoid screening process, from conception to application. Discover how these groundbreaking advancements are revolutionizing the prediction of drug efficacy and response, bridging the gap between the lab and clinical outcomes. Don't miss this opportunity to learn from the best and stay at the forefront of medical innovation!

The future we want, where ADRD can be easily detected and mitigated, starts with easier diagnostics—and blood-based biomarkers are a major step in the right direction. With these tools, we’ll have low-cost methods—key for testing patients more frequently. 

Dear CFO of scaleups Dear team of Hemotune AG Funding remains a key issue ! Great Sami (Finance) that Hemotune secures funds. The scaleup ecosystem needs to support longterm development. Overcoming Challenges: Simplify complexities, adapt with flexible scalability, prioritize compliance strategically, and master timing and funding for a seamless scale-up path. Join in shaping scale-up strategies and set up your company for success. https://www.fbxperts.ch 💼🌐 #ScaleUpStrategies #BusinessGrowth #InternationalizationDrivers#

We're thrilled to unveil our latest protocol with Cell Press for the RASTRUM Platform: a cutting-edge approach to creating 3D primary human hepatocyte (PHH) cell models. This breakthrough enables more accurate prediction of hepatotoxicity and enhances drug testing precision. 🔬 Key Highlights: - Develop 3D human hepatocyte models within a liver-relevant matrix using the RASTRUM Platform. - Maintain viable primary hepatocytes for up to 2 weeks for chronic drug exposure. - Assess vital metrics including albumin production, CYP450 activity, and drug response. - Utilize a 384-well plate format for efficient drug screening applications. Our new protocol empowers researchers to better simulate liver function and drug interactions, driving forward the future of hepatotoxicity studies. Dive into the details and elevate your research capabilities with RASTRUM: https://lnkd.in/gujMi78C #DrugDiscovery #DrugResearch #InventiaLifeScience

The #FDA recently granted Eli Lilly and Company and Roche a breakthrough designation to accelerate the development of their Elecsys pTau217 #BloodTest. As of late, pTau217 tests like ADDF-funded ALZpath Inc.'s have proven to be as accurate as the gold standard for #Alzheimers diagnostics—PET scans and spinal taps. With blood tests proving to be increasingly accurate in screening for Alzheimer's, the ADDF is optimistic that they will someday replace the more cumbersome and costly gold standard tests to become a diagnostic tool. Learn more about the collaboration and how blood tests could be a boon for improving diagnostic #accessibility and #scalability while supporting the rollout of the first class of Alzheimer's drugs in Fierce Biotech: https://bit.ly/4da17Hf